Compare · head to head
Day One Biopharmaceuticals vs Exelixis
Exelixis ranks higher overall — 360 rank 96 vs 39.
Exelixis leads on Value (65 vs 47), Quality (82 vs 62), Safety (64 vs 38) and Sentiment (46 vs 40).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Large |
| ISIN | US23954D1090 | US30161Q1040 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | — |
| Ranks | ||
| 360 | 39 | 96 |
| Value | 47 | 65 |
| Quality | 62 | 82 |
| Growth | NR | 49 |
| Safety | 38 | 64 |
| Sentiment | 40 | 46 |
| Quality details | ||
| Profitability | 58 | 96 |
| Cash Truth | 65 | 68 |
Full analyses: Day One Biopharmaceuticals · Exelixis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100